In accordance with Reg. 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we further share the FAQs to the investor presentation, as annexed.

AI summary - Q1 FY27 sales grew 27% y-y and 7% q-q; CEM up 75% y-y, CRAMS up 20% y-y - CRAMS has 65+ live projects; 70% non-pharma/agro sectors; new NMR machine added - CEM revenue includes 700 million from Baker Hughes; Ascend plant utilisation at 72% - Sectoral sales: Pharma 32.2%, Agro 9.5%, Oil & Gas 31.4%, Material Science 16.6% - LSM pricing up 22.5% y-y; volume down 22% y-y due to strategic reallocation - Capex FY27 expected at 3,000-3,500 million; new R&D centre ready by Q2 FY28 - EBITDA margin Q1 FY27 at 31.47%, guidance ~30% for FY27 - Working capital cycle slightly improved; debt at 5,215 million as of June 30, 2026